Table 4.

Myonuclei and SCs per 100 myonuclei pre and post intervention period

	Sedentary‐placebo		Sedentary‐ESA		Training‐placebo		Training‐ESA
	Pre	Post	Pre	Post	Pre	Post	Pre	Post
Myonuclei/fibre
Fibre type I	2.03 ± 0.19	1.91 ± 0.16	1.685 ± 0.201	1.42 ± 0.18	1.72 ± 0.12	1.55 ± 0.12	2.01 ± 0.27	1.44 ± 0.12
Fibre type II	2.21 ± 0.24	2.06 ± 0.17	2.03 ± 0.182	1.91 ± 0.29	1.84 ± 0.25	1.965 ± 0.25	2.18 ± 0.29	2.02 ± 0.27
Hybrid fibres	2a	2.50 (0.0–3.0)	2.75 (0.0–3.0)	1.05 (0.0––4.0)	NA	0 (0.0–2.0)	0.67 (0.0–1.3)	2.38 (0.0–2.7)
SC/100 myonuclei
Fibre type I	2.5 ± 1.0	3.0 ± 0.7	5.0 ± 0.8	5.5 ± 1.7	3.7 ± 0.8	2.9 ± 0.4	2.6 ± 0.7	5.3 ± 1.1
Fibre type II	2.7 ± 1.1	2.3 ± 0.7	2.9 ± 0.5	3.2 ± 0.5	2.0 ± 0.3	3.1 ± 0.6*	1.2 ± 0.5	3.2 ± 0.6*
Hybrid fibres	6.8a	0 (0.0–2.2)	1.3 (0.0–4.6)	8.3 (0.0–18.2)	NA	NA	2.7 (0.0–5.4)	0 (0.0–4.6)

Myonuclei per fibre and satellite cells per myonclei in type I, type II and hybrid fibres pre and post 10 weeks of sedentary‐placebo, sedentary‐ESA, training‐placebo or training‐ESA treatment. Data are the mean ± SE for type I and type II fibres and median (range) for hybrid fibres. Significant change from pre is indicated by * (P < 0.05). ^a n = 1 included in analysis. NA, not available.